Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells

Texto completo
Autor(es):
Ignarro, Raffaela Silvestre [1] ; Facchini, Gustavo [1] ; Vieira, Andre Schwambach [2] ; De Melo, Daniela Rodrigues [3] ; Lopes-Cendes, Iscia [2] ; Castilho, Roger Frigerio [3] ; Rogerio, Fabio [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Dept Anat Pathol, Fac Med Sci, Av Tessalia Vieira De Camargo 126, BR-13083887 Campinas, SP - Brazil
[2] State Univ Campinas UNICAMP, Dept Med Genet, Fac Med Sci, Av Tessalia Vieira De Camargo 126, BR-13083887 Campinas, SP - Brazil
[3] State Univ Campinas UNICAMP, Dept Clin Pathol, Fac Med Sci, Av Tessalia Vieira De Camargo 126, BR-13083887 Campinas, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Molecular and Cellular Biochemistry; v. 418, n. 1-2, p. 167-178, JUL 2016.
Citações Web of Science: 6
Resumo

Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma. This tumor type synthesizes the antioxidant glutathione through system X (c) (-) , which is inhibited by sulfasalazine (SAS). We exposed A172 and T98G human glioblastoma cells to a presumably clinically relevant concentration of TMZ (25 A mu M) and/or 0.5 mM SAS for 1, 3, or 5 days and assessed cell viability. For both cell lines, TMZ alone did not alter viability at any time point, while the coadministration of TMZ and SAS significantly reduced cell viability after 5 days. The drug combination exerted a synergistic effect on A172 cells after 3 and 5 days. Therefore, this particular lineage was subjected to complementary analyses on the genetic (transcriptome) and functional (glutathione and proliferating cell nuclear antigen (PCNA) protein) levels. Cellular pathways containing differentially expressed genes related to the cell cycle were modified by TMZ alone. On the other hand, SAS regulated pathways associated with glutathione metabolism and synthesis, irrespective of TMZ. Moreover, SAS, but not TMZ, depleted the total glutathione level. Compared with the vehicle-treated cells, the level of PCNA protein was lower in cells treated with TMZ alone or in combination with SAS. In conclusion, our data showed that the association of TMZ and SAS is cytotoxic to T98G and A172 cells, thus providing useful insights for improving TMZ clinical efficacy through testing this novel drug combination. Moreover, the present study not only reports original information on differential gene expression in glioblastoma cells exposed to TMZ and/or SAS but also describes an antiproliferative effect of TMZ, which has not yet been observed in A172 cells. (AU)

Processo FAPESP: 13/07559-3 - Instituto Brasileiro de Neurociência e Neurotecnologia - BRAINN
Beneficiário:Fernando Cendes
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
Processo FAPESP: 11/50400-0 - Metabolismo energético, estado redox e funcionalidade mitocondrial na morte celular e em desordens cardiometabólicas e neurodegenerativas
Beneficiário:Aníbal Eugênio Vercesi
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 13/02618-1 - Análise do estresse oxidativo induzido por sulfasalazina associado com a ação do quimioterápico temozolomida em células de glioma humano e de rato
Beneficiário:Fábio Rogério
Linha de fomento: Auxílio à Pesquisa - Regular